Plain-English translation of NCT06826118 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lymphoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called for patients with follicular lymphoma — a type of blood cancer — that has come back or stopped responding to previous treatments. The treatment works by collecting your own immune cells, training them in a lab to recognize and fight lymphoma, and then infusing them back into your body. Researchers want to see if this approach is safe and effective for patients in China who haven't had success with earlier therapies.
Follicular lymphoma is a slow-growing cancer that often comes back or stops responding to standard treatments like chemotherapy and antibody drugs. This trial exists because doctors need new options for patients who have already tried multiple treatments — and this medication represents a promising approach that harnesses the body's own immune system to fight the cancer.
You likely qualify if…
You likely don't qualify if…
You will first receive chemotherapy to prepare your body for the new treatment. Then doctors will collect about 8–10 liters of your blood to extract immune cells, which are sent to a lab where they are modified and grown over several weeks. Once ready, the trained cells are infused back into you. You'll have multiple visits for blood tests, scans, and check-ins to monitor how well the treatment works and watch for any side effects. The study will follow your progress over time as researchers track your response to this new therapy.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
The First Affiliated Hospital of Xiamen University
Enrollment target
~30 participants
Started
February 2025
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Bing Xu
The First Aiffiliated hosptical of xiamen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.